Acute lysine supplementation does not improve hepatic or peripheral insulin sensitivity in older, overweight individuals by unknown
Kim et al. Nutrition & Metabolism 2014, 11:49
http://www.nutritionandmetabolism.com/content/11/1/49RESEARCH Open AccessAcute lysine supplementation does not improve
hepatic or peripheral insulin sensitivity in older,
overweight individuals
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and Robert H Coker2*Abstract
Context: Lysine supplementation may have a positive influence on the regulation of glucose metabolism but it has
not been tested in the geriatric population. Objective: We evaluated the impact of acute lysine supplementation
using three randomized experimental scenarios: 1) oral glucose alone (control), 2) oral glucose and low-dose lysine
(2 grams), and oral glucose and high dose lysine (5 grams) lysine in 7 older (66 ± 1 years/age), overweight/obese
(BMI = 28 ± 2 kg/m2) individuals.
Methods: We utilized a dual tracer technique (i.e., [6,6-2H2] glucose primed constant infusion and 1-[
13C] glucose
oral ingestion) during an oral glucose tolerance test (OGTT) to examine differences in hepatic and peripheral insulin
sensitivity under all three scenarios.
Results: Post-absorptive plasma glucose and insulin concentrations were not different between the three trials.
Similarly, the response of glucose and insulin concentrations during the oral glucose tolerance tests (OGTT) was
similar in the three trials. The results of the Matsuda index (ISI/M) were also not different between the three trials.
As an index of hepatic insulin sensitivity, there were no significant differences in the endogenous glucose rate of
appearance (glucose Ra) for control, 2 g lysine and 5 g lysine (1.2 ± 0.1, 1.1 ± 0.1, 1.3 ± 0.1 mg•kg
−1•min−1),
respectively. With respect to peripheral insulin sensitivity, there were no significant differences in the glucose rate of
disappearance (glucose Rd) for control, 2 g lysine and 5 g lysine (4.2 ± 0.1, 4.3 ± 0.2, and 4.5 ± 0.4 mg•kg
−1•min−1),
respectively.
Conclusions: Previous studies in younger participants have suggested that lysine may have a beneficial effect on
glucose metabolism. However, acute lysine supplementation in the older population does not facilitate beneficial
changes in glucose Ra or glucose Rd.
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Cardiovascular disease (CVD) remains a leading cause of
death among US adults [1]. Elderly individuals are at
high risk for negative cardiovascular outcomes due to
age-related physiological changes that directly impact
the anatomy and function of the cardiovascular system
[2,3], as well as disease-related processes that are driven* Correspondence: rcoker@alaska.edu
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unless otherwise stated.by poor nutritional status, physical inactivity, and other
issues common at older ages [4,5]. In addition, the acceler-
ated loss of muscle mass (sarcopenia) that is typical
among elderly adults, combined with the increasing preva-
lence of obesity in this population [6] present additional
difficulties when choosing an appropriate therapeutic
course of action in this population.
Hyperglycemia is one important factor that directly
influences vascular complications associated with CVD
and represents a central therapeutic target for managing
CVD-related outcomes in elderly adults. Although recent
trials have demonstrated that intensive glucose control. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment in older patients with advanced type 2 diabetes [7,8],
tight glycemic control was associated with slowed progres-
sion of retinopathy [9,10] and may especially reduce the
risk of micro- and macrovascular disease when started
earlier in the disease course [11]. The ingestion of protein
with glucose has been shown to augment insulin secretion
and diminish the plasma glucose response in persons with
type 2 diabetes [12]. It has been recently reported that
lysine (a readily abundant essential amino acid), when
ingested with glucose, facilitates a reduction in the glucose
area under the curve (AUC) by 44% without any change
in plasma insulin, along with a reduction in plasma glu-
cagon [13]. Thus, lysine supplementation may repre-
sent a novel and cost-effective therapeutic intervention
to reduce hyperglycemia and related CVD outcomes
without potential complications associated with other
nutritional, behavioral, or pharmacological interventions.
It is not known whether acute lysine supplementation in
the previously mentioned study [13] promoted improved
glucose metabolism through 1) an increased suppression
of endogenous glucose production (glucose Ra), 2) in-
creased glucose disappearance (glucose Rd), or 3) both.
Second, since almost all of the study subjects experienced
some sort of mild gastrointestinal distress with higher
doses of lysine, the efficacy of a lower dose of lysine re-
quires investigation. In order to validate these preliminary
studies and investigate the site of action, we propose to
use a dual tracer technique ([1-13C] glucose oral ingestion
and [6,6-2H2] glucose primed constant infusion) that will
allow us to selectively delineate endogenous glucose Ra,
exogenous glucose Ra, and endogenous glucose Rd [14].
In this way, we will be able to determine the primary
mechanism (increased suppression of glucose Ra, improved
glucose Rd or both) responsible for the improvement in
glucose AUC.
Therefore, the primary objective of this study was to de-
termine the efficacy of acute lysine supplementation on
glucose metabolism in older, overweight individuals. In
addition, we incorporated the application of stable isotope
tracer methodology coupled with an OGTT that allowed
us to determine the site of action (hepatic and/or periph-
eral) that was influenced by lysine supplementation. To
our knowledge, the influence of lysine supplementation
on hepatic and peripheral glucose metabolism when given
in combination with an OGTT has not been investigated.
The practical implications of a readily available, efficacious
nutrient that could be used to promote more effective glu-
cose homeostasis have important implications.
Methods
Subjects
Seven overweight/obese older Caucasian subjects (66 ±
4 yr, 4 M, 3 F, 175 ± 7 cm, 98.3 ± 9.6 kg, body massindex = 32 ± 2.2 kg●m−2; % fat = 33.6 ± 3.4, means ± SD)
participated. All subjects were weight stable, and
ranged between normal glucose tolerance (NGT) and
impaired glucose tolerance (IGT). Participants underwent
a physical examination, which included a medical history,
blood chemistry, measurement of vital signs and body
weight (within 0.1 kg). A resting electrocardiogram (EKG)
and dual X-ray absorptiometry (DXA) scan were also
performed at baseline. Participants taking medicines or
supplements that might have had potential effects on
metabolism were excluded. Each participant provided
written informed consent, and study procedures were ap-
proved by the Institutional Review Board of the University
of Arkansas for Medical Sciences (UAMS).
Study design
The order of the visits was randomly assigned to the three
supplements 1) glucose alone or control, 2) glucose + low
dose and 2 g lysine (2 L), and 3) glucose + high dose or 5 g
lysine (5 L). The research staff administered these sup-
plements in conjunction with a dual tracer technique
(i.e., [1-13C]glucose oral ingestion and [6,6-2H2] glucose
primed constant infusion) during an oral glucose tolerance
test (OGTT-DT) on three separate occasions with a 2
week wash out period between each metabolic study. The
supplements provided were identical in appearance. The
[6,6-2H2] glucose tracer was primed constantly infused
[prime, 82.2 umol/kg; rate, 0.78 umol•kg−1•min−1]. Inges-
tion of 1-[13C] glucose was concurrent with the oral glu-
cose test drink +/− lysine supplement and was based on
40 mg/kg (15). Randomization to the order of the study
visits was determined prior to enrollment.
Blood samples (t = −150, −140, and −130 min) were
collected prior to the onset of the OGTT-DT protocol,
and serial blood samples (t = 30, 45, 60, 70, 80, 90, 105,
and 120 min) were collected during the remainder of the
study into EDTA-containing tubes and centrifuged at
3,500 rpm for 15 min at 4°C. Oral glucose was provided
as Sundex ® (Thermo Fisher Scientific, Waltham, MA)
and lysine was administered as L-lysine dissolved into
deionized water at a concentration of 50 g/100 mL
(Ajinomoto USA Inc., Raleigh, NC) (Figure 1). Stable
isotopes were obtained as sterile powders (Cambridge
Isotope Labs, Andover, MA), and were professionally pre-
pared under aseptic conditions by a Research Pharmacist
at UAMS. The dual tracer technique utilized the simul-
taneous infusion and ingestion of glucose tracers to
trace the metabolic fate of ingested and endogenously-
produced glucose. Our primary endpoints were glucose
Ra and glucose Rd (Figure 1). This approach allowed us
to determine the variable impact of lysine co-ingestion
with glucose on the hepatic and peripheral mechanisms
that may be responsible for potential improvements in
glycemia.
Figure 1 Isotope tracer infusion protocol.
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Whole-body insulin sensitivity was estimated by the
Matsuda Insulin Sensitivity Index (ISI/M) = 10000/
square root of ([fasting glucose × fasting insulin] ×
[mean glucose × mean insulin during OGTT]) [15]. We
calculated glucose AUC and insulin AUC using the trap-
ezoidal rule applied to the insulin and glucose responses
during the OGTT [16]. Insulin sensitivity in the post-
absorptive state was evaluated using the homeostasis
model assessment (HOMA-IR) index that is calculated
by dividing the product of fasting plasma glucose and
fasting plasma insulin by 22.5 [17]. Calculation of the
insulinogenic index was completed using the equation:
(Ins30 –Ins0/Glucose30 Glucose0). The disposition index
was calculated as the product of the Matsuda index and
the insulinogenic index [18].
For calculation of glucose kinetics the Steele equation
was used for the non-steady state [19]. This approach has
been widely discussed for at least 50 years. The major
issue with regard to calculating glucose kinetics with the
Steele equation is that a factor is used to account for the
fact that the glucose pool does not behave as a single,
rapidly-mixing pool. The assumption underlying the cor-
rection factor is that there is some fraction of the total glu-
cose pool that acts as a single, well-mixed pool in the
acute, non-steady state circumstance. We have used differ-
ent approaches, both experimental and theoretical, to in-
vestigate the correct volume of distribution for use with
the Steele equation for glucose kinetics [20,21]. The con-
clusion from these studies was that there is no unique
value that results in the correct calculation of glucose Ra
in all circumstances. Glucose Ra is relatively accurately cal-
culated during acute changes in isotopic enrichment when
a relatively small value approximating plasma volume
(40 ml/kg) is used. As a new isotopic equilibrium is
approached, changes in plasma enrichment of glucose re-
flect a volume of distribution significantly greater than the
plasma volume, with a value as large as 200 ml/kg being
optimal. It is impossible to anticipate a priori the most ap-
propriate value at any given time. Rather, it is necessary to
choose a single value and use that value throughout the
entire experiment. It has been our practice to use a small
(40 ml/kg) value for the reason that the acute responses
are consistently more accurately predicted, and the factthat the importance of the exact volume used becomes less
important as a new isotopic equilibrium is approached.
This is because the difference in isotopic enrichment
between samples diminishes as a new equilibrium is
approached, so the volume is multiplied by a diminish-
ingly small number [22]. In the current study, we calcu-
lated glucose Ra using values of 40 ml/kg and 200 ml/kg
to estimate the upper and lower bounds of glucose Ra in
the non-steady state. As predicted from our earlier work,
in every case the magnitude of the acute change in glucose
Ra from the basal value was markedly greater when
200 ml/kg was used, and as a new equilibrium was
approached the values became similar regardless of the
volume used in the calculation. We have presented in the
current paper only the results from the calculation using a
value of 40 ml/kg, because the initial changes in glucose
Ra calculated using 200 ml/kg were likely overestimates of
the true response [22]. Use of different volumes did not
affect our conclusions, only the magnitude of the early
response.
Plasma glucose tracer enrichments and concentrations
were curve-fitted with a 3-order polynomial model
over the OGTT period in Graphpad Prism 5 for Mac
(Graphpad Software, Inc. La Jolla CA). Enrichment (E)
is expressed as mole percent excess (MPE): MPE is calcu-
lated as TTR/(1 +TTR), where TTR is tracer to tracee ratio.
Appropriate corrections for skew abundance distribution
and overlapping spectra for TTR of 1-[13C] gluscoe and
6,6-[2H2] glucose were made, respectively [22]. From these
calculations, total glucose Ra is comprised of ingested
glucose, hepatic glucose production, and negligible renal
glucose production or splanchnic glucose Ra:
Total glucose Ra = (F – (pV • (C2 + C1) / 2) • ((E2 – E1) /
(t2 – t1))) / (E2 + E1) / 2 [1].
Glucose Rd = Total glucose Ra – pV • (C2 – C1) /
(t2 – t1) [2].
Exogenous glucose Ra = Total glucose Ra • (EP / ED) [3].
Endogenous glucose Ra = Total glucose Ra – Exogenous
glucose Ra [4].
MCR =Glucose Rd / ((C1 + C2) / 2) [5].
Where F represents the infusion rate of 6,6-[2H2] glu-
cose; pV is the effective volume of distribution for glucose,
for which 40 ml•kg−1 was used; C1 and C2 are plasma glu-
cose concentrations at specific times t1 and t2, respectively,
Figure 2 Plasma concentrations of glucose and insulin during
the OGTT-DT in the control, 2 grams lysine, and 5 grams of
lysine. Data are mean ± SEM. Significant increase over time for all
three groups (P < 0.05).
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2H2] glucose at
specific times t1 and t2, respectively; ED and EP are enrich-
ments of 1-[13C] glucose from the test drink and plasma,
respectively.
Data handling and recordkeeping
All data and research material were obtained specifically
for research purposes and were made available only to
the medical staff and the principal investigator or his
associates. These data included demographic data, body
composition data, multiple blood samples, glucose meta-
bolic testing data, screening laboratory data, and a full
medical history.
The UAMS pharmacy performed the randomization;
repackaging and relabeling of supplements. The supple-
ments were similar in appearance and labeled with the
pre-selected randomization codes. Randomization codes
were saved at the Institute on Aging in a sealed enve-
lope. The seal was broken at the end of the study; and
after the blood samples had been analyzed.
Statistical and power analyses
An analysis of covariance model was employed to assess
the effects of lysine intake (5 and 2 g/day) on hepatic
and peripheral glucose metabolism in older, obese par-
ticipants. Two levels of acute lysine intake were included
as factors in the model, while hepatic and glucose me-
tabolism were included as covariates.
Initially, a lysine-by-glucose metabolism interaction
term was included in the model and tested. If the inter-
action term was significant, then the effect of lysine
intake on glucose metabolism was tested separately for
hepatic and peripheral tissue. A 5% α-level was used to
determine statistical significance for tests of main effects,
while a 10% α-level was used to test the interaction
effect.
Results
Additional file 1: Table S1: Clinical Characteristics.
Glucose. Fasting plasma glucose (112 ± 5, 111 ± 5 and
112 ± 5 mg/dl for the conditions of the control, 2 L and
5 L, respectively) represented impaired glucose tolerance
and were not significantly different. Plasma glucose in-
creased (P < 0.0001), and in a similar fashion (P = 0.91)
in all three experimental scenarios during the OGTT-
DT (Figure 1). Glucose AUC was similar (P = 0.86) at
19247 ± 1794, 17617 ± 1088 and 17193 ± 1175 mg/
dl●120 min for the control, 2 L and 5 L during the
OGTT-DT.
Plasma Insulin. Fasting plasma insulin was 10.6 ± 1.5,
12.0 ± 1.7 and 11.3 ± 1.0 uU/ml in the control, 2 L and
5 L conditions, respectively, and increased (P < 0.0001)
without any significant difference (P = 0.71) between the
conditions during the OGTT-DT (Figure 2). Insulin AUCwas similar (P = 0.72) at 8979 ± 2020, 11730 ± 2864, and
10573 ± 2226 uU/ml ≅ 120 min for the control, 2 L and
5 L, respectively.
Insulin Sensitivity. The HOMA-IR index was 2.6 ± 0.3,
3.4 ± 0.6, and 3.2 ± 0.4, and was similar (P = 0.44) for the
control, 2 L and 5 L. Insulin sensitivity calculated from
the ISI/M was similar (P = 0.86) at 3.3 ± 0.6, 3.0 ± 0.6 and
2.9 ± 0.5 for control, 2 L and 5 L, respectively.
Insulinogenic and Disposition Index. With respect to
differences in peripheral changes in insulin and glucose
during the OGTT, there were no significant differences
based on the insulinogenic index (1.4 ± 0.4, 1.3 ± 0.43,
and 2.0 ± 0.7) (p = 0.6598) between control, 2 L, and 5 L,
respectively. There were also no significant differences in
the disposition index (3.8 ± 0.9, 3.3 ± 0.4, and 1.7 ± 0.2)
(P = 0.08), respectively.
Glucose Enrichments. Initially, the 6,6-2[H2] glucose
MPE was similar (P = 0.68) and decreased (P < 0.0001)
without any significant variation between the control, 2 L
or 5 L (Figure 3). The 1-[13C] MPE was also similar at
baseline (P = 0.91), but increased similarly in the control,
2 L and 5 L (Figure 3).
Glucose Kinetics. Total Glucose Ra was not different
(P = 0.49) between the control, 2 L and 5 L during the
OGTT-DT (Figure 4). Exogenous glucose Ra increased
(P < 0.0001) during the OGTT-DT and was not differ-
ent (P = 0.63) between the control, 2 L and 5 L. En-
dogenous glucose Ra decreased (P < 0.0001) in the control
(1.7 ± 0.1 to 0.8 ± 0.1 mg•kg−1•min−1), 2 L (1.9 ± 0.1 to
Figure 3 Plasma enrichment, expressed as mole percent excess (MPE), for 1-[13C] glucose and 6,6-[2H2] glucose during the OGTT-DT in
the control, 2 grams lysine, and 5 grams of lysine. Data are mean ± SEM. Significant decrease over time for all three groups (P < 0.05).
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0.1 mg•kg−1•min−1) and was not different between
groups (Figure 4). Glucose Rd increased (P < 0.0001) in
a similar fashion (P = 0.69) in the control (3.8 ± 0.3 to
4.4 ± 0.2 mg•kg−1•min−1), 2 L (3.4 ± 0.3 to 4.7 ±
0.4 mg•kg−1•min−1) and 5 L (3.4 ± 0.3 to 4.9 ±
0.4 mg•kg−1•min−1) (Figure 4). Independent of the differ-
ences in glucose concentration, the metabolic clearance
rate increased in a similar fashion (P = 0.69) in the con-
trol (2.3 ± 0.3 to 3.0 ± 0.4 ml/kg•min−1), 2 L (1.9 ± 0.3
to 3.2 ± 0.4 ml/kg•min−1) and 5 L (2.1 ± 0.3 to 3.0 ±
0.5 ml/kg•min−1) (Figure 4).
Discussion
Previous studies have suggested the potential efficacy of
acute lysine supplementation on glucose metabolism. InFigure 4 Glucose kinetics during the OGTT-DT in the control, 2 grams
increase over time for all three groups (P < 0.05).an effort to clearly delineate the potential mechanisms
responsible for lysine-induced improvements in glucose
metabolism, we utilized a dual tracer ([6,6-2H2] glucose
primed constant infusion and [1-13C]glucose oral in-
gestion) during an oral glucose tolerance test in older,
overweight individuals. Instead of relying solely on glucose
AUC, HOMA-IR, or ISI that may have interpretative
limitations in acute or intervention-based studies [16],
this dual tracer approach allowed us to clearly delineate
glucose kinetics during OGTT, which is commonly uti-
lized in the clinical setting. Nonetheless, the data gener-
ated from all methods were uniformly consistent, and our
results were not consistent with our original hypotheses.
In fact, we found no significant differences in glucose
AUC, HOMA-IR or ISI between lysine supplementation
and control. More specifically, lysine supplementation hadlysine, and 5 grams of lysine. Data are mean ± SEM. Significant
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insulin sensitivity) or glucose Rd (indicative of peripheral
insulin sensitivity). The MCR of glucose was also similar
in the control, 2 L and 5 L, highlighting the lack of any
difference in the amount of lysine ingestion on glucose
kinetics.
Our results were a bit surprising given that previous
studies utilizing lysine supplementation in younger,
healthy individuals described beneficial changes in the
glucose AUC [13]. While it has been known for almost
50 years that amino acids promote the release of insu-
lin [23], the positive results of the previous lysine sup-
plementation studies occurred without a difference in
peripheral insulin during the OGTT [13]. In another
previous study utilizing a combination of arginine/ly-
sine, there was no influence of plasma insulin, glucose
or glucose AUC [24]. This is significant for many reasons,
including the well-established relationship between the in-
fusion or ingestion of amino acids and the insulinotrophic
response that mediates potentially beneficial effects on
glucose metabolism [23]. Even in the earlier studies that
demonstrated positive results on glucose metabolism,
wide variations were described among essential amino
acids with regard to the release of insulin [23]. We found
that acute lysine supplementation did not seem to stimu-
late insulin secretion as reflected by almost identical
plasma insulin levels in all three conditions, and this cor-
roborates the findings of the most recent study involving
lysine supplementation in younger individuals [13]. On
the other hand, we did not measure C-peptide in the
present study and this precludes us from knowing
whether differences in hepatic clearance contributed to
relatively equivalent peripheral insulin concentrations.
The discrepancy in the plasma insulin response is most
likely due to 8–10 fold differences in the amount of
amino acid ingested in the different studies. With in-
gestion of a modest amount of lysine there is no re-
sponse of plasma insulin and consequently no effect on
glucose metabolism. Further, since the study popula-
tion in the present study were older, overweight/obese
adults with lower doses of lysine (2 or 5 g of lysine) as
compared to healthy young adults with a wide range of
BMI (21 – 39 kg●m−2) in the previous study with higher
doses of lysine (mean, 11 g; range, 6 – 13 g) [13], the null
effect of acute lysine supplementation on glucose metabol-
ism in the present study can be attributed to two factors:
1) doses of lysine ingestion and 2) age. First, the lower ly-
sine doses in the present study may be simply insufficient
to produce a favorable effect on glucose metabolism.
Second, there may be an age-associated resistance to a
lower dose of lysine ingestion with respect to glucose
metabolism as in the case for muscle protein synthesis
response. It has been shown that with an advancing age,
muscle protein synthesis (MPS) response to a smalleringestion of EAAs (7 g) was reduced in older individ-
uals as compared to young individuals [25], which was
overcome by a larger ingestion of EAAs (15 g) [26].
Therefore, it is worth investigating whether ingestion
of lower doses of lysine as in the case of the present
study could improve glucose metabolism in healthy
young adults.
The dual tracer method in the context of OGTT is not
a new technique, and has been used extensively to
evaluate potential changes in glucose metabolism [14,27].
Inappropriate estimation of the effective volume of dis-
tribution for glucose can lead to erroneous variations
including the almost complete suppression of endogen-
ous glucose Ra in overweight individuals with insulin
resistance [28]. In the present study, endogenous glu-
cose Ra decreased gradually and consistently in all three
conditions without consistent and subtle variations in
[6,6-2H2]glucose and [1-
13C]glucose enrichments. In
addition, endogenous glucose Ra increased as antici-
pated throughout the OGTT with any variation be-
tween the three conditions. Our approach was further
strengthened by the randomized design utilizing the
same participants.
The influence of glycine [29], proline [30], arginine
[31], phenylalanine [32], and leucine [33] on glucose
metabolism has been evaluated. Of these, leucine and
phenylalanine seem to promote efficacious changes in
glucose metabolism [32,33]. Despite very few studies to
support its efficacy, lysine supplements are often mar-
keted to improve the regulation of glucose metabolism
in diabetes and metabolic syndrome without sufficient
clinical evidence. This may be largely based on the con-
tention that the co-ingestion of protein with glucose has a
synergistic influence on the release of insulin [12]. In so
far as lysine itself is concerned, it only seems to function
as a powerful insulin secretagogue when ingested in
higher amounts (i.e., >11 grams) or in the context of a
high protein meal [12]. One of the reasons that we chose
to evaluate responses to 2 and 5 grams of lysine were due
to previous reports of gastrointestinal distress, primarily
diarrhea, with higher doses. This would contraindicate the
use of lysine in older adults. Notably, there were no re-
ports of gastrointestinal distress in the current study.
We evaluated the influence of acute lysine supple-
mentation on glucose metabolism using a randomized
experimental design in the same subjects. We found
that acute lysine ingestion at moderate doses (i.e., 2
or 5 g) has no favorable influence on endogenous
glucose Ra, endogenous glucose Rd, glucose AUC, in-
sulin AUC or ISI/M in older, overweight individuals.
Given that larger doses may be required, future studies are
needed to evaluate whether the risk of gastrointestinal
distress might outweigh the therapeutic benefit of lysine
ingestion.
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